Share

Networks

Clinical Studies (1)

  • PanoramicNOR : Study aims to assess whether a 5-day course of nirmatrelvir/ritonavir treatment for patients with acute COVID-19 can reduce the prevalence of persistent symptoms at 3 months compared to placebo

Study Data

  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post COVID-19 condition
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir

Other information

If you would like to contact the site, please email: ccb@ateneo.univr.it

The data is updated up to